Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01081951 · ClinicalTrials.gov registry record · Phase 2

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

A Phase 2 study of Ovarian Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 2
Development phase
162
Enrollment target
20
Study locations

NCT01081951 is a Phase 2 study of Ovarian Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 162 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01081951, a Phase 2 study of Ovarian Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
162 participants
Enrollment target
20
Study locations

Study Summary

To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.

Conditions Studied

Ovarian Cancer

Interventions

  • DRUG carboplatin
  • DRUG paclitaxel
  • DRUG olaparib
  • DRUG Drug: carboplatin

Study Locations (20)

Other

  • Research Site - Parkville
  • Research Site - Randwick
  • Research Site - Brussels
  • Research Site - Leuven
  • Research Site - Namur
  • Research Site - Wilrijk

Ontario

  • Research Site - Hamilton
  • Research Site - Toronto
  • Research Site - Toronto

California

  • Research Site - Stanford
  • Research Site - West Hollywood

Massachusetts

  • Research Site - Boston
  • Research Site - Boston

Quebec

  • Research Site - Québec
  • Research Site - Sherbrooke

Florida

  • Research Site - Orlando

Indiana

  • Research Site - Indianapolis

New York

  • Research Site - New York

Trial Details

FieldValue
Enrollment Target 162 participants
Start Date 2010-02-04
Est. Completion 2026-12-31
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01081951

The ClinicalTrials.gov registry entry for NCT01081951 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (78% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 4 interventions - of which carboplatin is the first listed.

NCT01081951 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Ontario, California.

Frequently Asked Questions

What is clinical trial NCT01081951 about?

NCT01081951 is a clinical study titled "Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer". To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.

What is the current status of trial NCT01081951?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2010-02-04. Estimated completion is 2026-12-31.

What conditions does trial NCT01081951 study?

This clinical trial studies the following conditions: Ovarian Cancer.

What interventions are being tested in trial NCT01081951?

The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), olaparib (DRUG), Drug: carboplatin (DRUG).

Who is sponsoring clinical trial NCT01081951?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01081951 being conducted?

This trial has 20 study locations across California, Florida, Indiana, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ovarian Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.